Research has revealed what we already suspected—randomized controlled trials are lacking in the field of bladder cancer. Many areas require further investigation, and we must try to incentivize clinicians to perform the much-needed trials. A newly established patient advocacy group will be invaluable in this endeavour.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bachir, B. G. et al. Demographic analysis of randomized controlled trials in bladder cancer. BJU Int. http://dx.doi.org/10.1111/j.1464-410X.2012.11401.x.
Jemal, A. et al. Cancer Statistics, 2008. CA Cancer J. Clin. 58, 71–96 (2008).
Ries, L. A. G. et al. SEER Cancer Statistics Review, 1975–2004 [online], (2007).
Heney, N. M. et al. Superficial bladder cancer: progression and recurrence. J. Urol. 130, 1083–1086 (1983).
Lotan, Y. et al. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer 115, 4096–4103 (2009).
Soloway, M. S., Bruck, D. S. & Kim, S. S. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J. Urol. 170, 438–441 (2003).
Herr, H. W. Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder? BJU Int. 88, 683–685 (2001).
Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54, 303–314 (2008).
Schmitz-Drager, B. J. et al. in Bladder Cancer 2nd Edn (eds Soloway, M. & Khoury, S.) 171–205 (European Association of Urology, Paris, 2012).
The author declares he has acted as a consultant and received grant/research support (inc. clinical trials) from Allergan, Photocure and Sanofi-Aventis.
About this article
Cite this article
Soloway, M. Lack of progress in bladder cancer—what are the obstacles?. Nat Rev Urol 10, 5–6 (2013). https://doi.org/10.1038/nrurol.2012.219
A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer
Journal of Experimental & Clinical Cancer Research (2021)
Cell Death & Disease (2021)
Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer
Frontiers in Oncology (2020)
Cancer stem cell-specific expression profiles reveal emerging bladder cancer biomarkers and identify circRNA_103809 as an important regulator in bladder cancer
Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad3 axis
Cell Death & Disease (2020)